Teva Pharmaceuticals

1710 articles with Teva Pharmaceuticals

• Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

  1/19/2023

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint.

• Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023

  1/12/2023

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2022 financial results, as well as on its financial guidance for 2023, on Wednesday, February 8, 2023 at 7:00 a.m. ET.

• Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

  1/6/2023

  Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has accepted for review a Biologics License Application for AVT04, Alvotech’s proposed biosimilar to Stelara®, which is prescribed to treat a variety of inflammatory conditions.

• Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Teva Pharmaceutical Industries Ltd. announced that members of management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023.

• Teva Announces Appointment of Richard Francis as President and CEO

  11/21/2022

  Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company’s Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023.

• 

  Teva Pharma Appoints Novartis, Biogen Vet as New President and CEO

  11/21/2022

  Teva Pharmaceuticals has found its new president and CEO. Effective Jan. 1, 2023, Richard Francis will take the company's reins as Kåre Schultz retires.

• Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform

  11/14/2022

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives.

• Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform

  11/14/2022

  Teva Pharmaceuticals today announced a new collaboration with HealthSnap, a leading full-service Virtual Care Management Platform for chronic disease management.

• Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting

  11/7/2022

  Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new findings from the CONNECT clinical trial program assessing the use of the Digihaler System compared to standard of care (SoC) in asthma management will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific meeting.

• Teva Reports Third Quarter 2022 Financial Results

  11/3/2022

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2022.

• Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease

  10/18/2022

  Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO ® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease.

• Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims

  10/7/2022

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General of Arkansas to settle the state’s price-fixing claims against Teva.

• Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes

  10/6/2022

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the initiation of a 3-year longitudinal registry and study to assess the impact of tardive dyskinesia (TD) and real-world treatment patterns and outcomes.

• Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022

  10/6/2022

  Teva Pharmaceutical Industries Ltd. announced that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET.

• Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea

  9/26/2022

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of the Honestly HD website, which aims to provide information, inspiration and resources to help people understand what to expect with Huntington’s Disease chorea – one of the most visible and treatable symptoms of HD – and, how to talk to their doctor about preserving independence.

• Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression

  9/8/2022

  Teva Pharmaceutical Industries Ltd. announces the results of two studies1,2 presented at the Migraine Trust International Symposium in London, UK, which demonstrate the efficacy of AJOVY▼ in migraine patients who also experience depression or anxiety.

• CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management

  9/7/2022

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that full results from the CONNECT1 study evaluating the ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and the Digihaler System in the management of asthma patients compared to standard of care (SoC) albuterol reliever therapy, were published online ahead of print in The Journal of Allergy and Clinical Immunology: In Practice.

• Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022

  8/29/2022

  Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir ® Digihaler ® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022.

• Phase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using MedinCell’s Technology

  8/29/2022

  Teva Pharmaceuticals has notified MedinCell (Paris:MEDCL) that it made the decision to initiate the clinical Phase 3 trial for mdc‑TJK.

• European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries

  8/29/2022

  Teva Pharmaceutical Industries Ltd. announces that the European Commission has granted a Marketing Authorization for Ranivisio, a biosimilar of the ophthalmology treatment Lucentis across all five indications in adults for which Lucentis is authorized.